title: [Treatment of bone disorders in renal diseases].
abstract: OBJECTIVE
  To study possible correction of bone disorders (osteopenia, Ca/P-imbalance, bone pain, limited volume of indolent movements) which are still a serious complication associated with renal diseases and pathogenic therapy (steroids).
  
  
  METHODS
  The bone disorders were treated in 10 uremic hemodialyzed patients (8 men, 2 women; group 1) with vitamin D3 (calcitriol made in Russia) + rhEPO (recormon; Boehringer Mannheim), in 15 patients (15 women, 0 men) with lupus-nephritis (group 2) with vitamin D3 (n = 5, group 2a) or miscalcic (Sandoz) (n = 10, group 2b), in 2 patients (2 men, 0 women) with glomerulonephritis (group 3) with vitamin D3 + miacalcic. Additionally all the patients received Ca salts. In groups 2 and 3 renal function was normal. The duration of the treatment was 3-6 months.
  
  
  RESULTS
  In all the groups we obtained an analgetic effect (attenuation of bone pain and more indolent movements), improvement of life quality, diminished need in analgetics, elevation of serum Ca level (p > 0.05).
  
  
  CONCLUSIONS
  Treatment of renal patients with bone affection with vitamin D3 and miacalcic has an analgetic effect, improves life quality.
authors.forename: A V
authors.initials: AV
authors.lastname: Kukhtevich
authors.forename: T N
authors.initials: TN
authors.lastname: Krasnova
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Nikolaev
authors.forename: S S
authors.initials: SS
authors.lastname: Rodionova
authors.forename: L Iu
authors.initials: LIu
authors.lastname: Milovanova
mesh_terms: D000328:Adult; D000700:Analgesics / Q000627:therapeutic use*; D001847:Bone Diseases / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D002116:Calcitonin / Q000627:therapeutic use*; D002118:Calcium / Q000627:therapeutic use; D002762:Cholecalciferol / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D005921:Glomerulonephritis / Q000150:complications* / Q000523:psychology / Q000628:therapy; D006801:Humans; D008181:Lupus Nephritis / Q000150:complications / Q000523:psychology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D011994:Recombinant Proteins; D006435:Renal Dialysis; D016896:Treatment Outcome; D014511:Uremia / Q000150:complications* / Q000523:psychology / Q000628:therapy
chemical_list: D000700:Analgesics; D011994:Recombinant Proteins; D004921:Erythropoietin; D002762:Cholecalciferol; C028815:salmon calcitonin; D002116:Calcitonin; D002118:Calcium